Patent ID: 8513275
Filing Date: 2013-08-20
Classification: A61K,A61P,C07D

Abstract:
1. A rifaximin polymorph Form kappa, a rifaximin polymorph Form theta, a rifaximin:piperazine cocrystal 1 or a rifaximin:piperazine cocrystal 2 wherein: the polymorph Form kappa exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at the polymorph Form theta exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at the rifaximin:piperazine cocrystal 1 exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at the rifaximin:piperazine cocrystal 2 exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at